Newsroom | 211870 results

NEW YORK--(BUSINESS WIRE)--Veracity Launches Metabolic Power Protein: A Smarter Protein Designed to Strengthen Your Metabolism Without Toxicity....

NUEVA YORK--(BUSINESS WIRE)--Blue Matter tiene el orgullo de anunciar que ha establecido un área de práctica que prestará exclusivamente servicios a los clientes en investigación y desarrollo (I+D) biofarmacéutico. La dirección de esta práctica estará a cargo de Tara Austraat-Churik, una socia que se incorporó a la firma en septiembre de 2025. Tara Austraat-Churik tiene más de 20 años de experiencia en servicios a los clientes del sector de las ciencias de la vida. Se ha especializado en las ár...

NEW YORK--(BUSINESS WIRE)--Blue Matter a le plaisir d'annoncer la création d'un domaine d'expertise dédié aux clients du secteur de la recherche et développement biopharmaceutique. Ce domaine est dirigé par l'associée Tara Austraat-Churik, qui a rejoint le cabinet en septembre 2025. Tara Austraat-Churik accompagne les acteurs des sciences de la vie depuis plus de 20 ans. Ses domaines d'expertise comprennent le développement et la mise en œuvre de stratégies, la conception de modèles opérationne...

NEW YORK--(BUSINESS WIRE)--Blue Matter annuncia la creazione di una nuova area di consulenza dedicata ai clienti del settore R&S biofarmaceutico e diretta da Tara Austraat-Churik, partner unitasi a Blue Matter nel settembre 2025. Tara Austraat-Churik vanta un’esperienza di oltre 20 anni al servizio di clienti nel settore delle scienze della vita. Molteplici le sue aree di competenza – sviluppo e implementazione di strategie, progettazione di modelli operativi e organizzativi, ottimizzazione...

NEW YORK--(BUSINESS WIRE)--Blue Matter hat einen neuen Praxisbereich gegründet, der auf die Bedürfnisse von Kunden aus der biopharmazeutischen Forschung und Entwicklung (FuE) ausgerichtet ist. Geleitet wird der Praxisbereich von Tara Austraat-Churik, einer Partnerin, die seit September 2025 für Blue Matter tätig ist. Tara Austraat-Churik ist bereits seit über 20 Jahren für Life-Science-Kunden tätig. Ihre Schwerpunkte sind Strategieentwicklung und -umsetzung, Betriebsmodell- und Organisationsges...

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced a new initiative with the Canadian Foundation for the Advancement of Orthodontics (CFAO). Under this initiative, Align has committed to support Invisalign treatment for 30 eligible pati...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate...

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology & Pharmaceuticals, Inc. (Allele), a San Diego-based technology development and cell manufacturing company, today announced its participation in an up to $25.8 million research project with the University of California, San Diego, funded by the Advanced Research Projects Agency for Health (ARPA-H). The project’s goal is to develop a fully functional, patient-specific, 3D bioprinted liver for transplantation. This project is under ARPA-H’s Pers...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Orthopedic Care Partners (OCP) welcomes Rob Passaro as Vice President of Business Development. His appointment supports OCP’s ongoing growth initiatives, strengthens its market presence, and contributes to building long-term value with physician partners. Passaro brings nearly twenty years of healthcare and business development expertise, having held leadership roles within high-growth, physician-led, and private equity-backed organizations. His experience in...

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, is reiterating its previously announced 2025 guidance and providing its preliminary financial outlook for 2026. The Company expects to continue its low double-digit adjusted EBITDA growth trajectory in 2026, supported by the strength of its operating model and increased visibility into the year ahead, including anticipated drug pricing changes. The C...